Mga Batayang Estadistika
| LEI | 54930042TDFRLM4C8X19 |
| CIK | 1496671 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Calithera Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 5, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| May 26, 2023 |
CALA / Calithera Biosciences Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo MO 103-8668 Yoshihiro Nak |
|
| May 26, 2023 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Calithera Biosciences, Inc. |
|
| May 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 22, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36644 CALITHERA BIOSC |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36644 Calithera Biosciences, Inc. (Exact name of registrant as s |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 POS AM As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| February 14, 2023 |
US13089P5070 / Calithera Biosciences Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233236-13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Calithera Biosciences, Inc (Name of Issuer) Common Stock, par value $0.0001 per share (the “Share |
|
| February 14, 2023 |
SC 13G/A 1 sc13ga707422cala02142023.htm AMENDMENT NO. 7 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 Calithera Biosciences, Inc. (Name of Issuer) Common Stock, $0. |
|
| February 9, 2023 |
SC 13G/A 1 calaa620923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Calithera Biosciences, Inc. (Name of Issuer) COM (Title of Class of Securities) 13089P507 (CUSIP Number) January 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2023 |
SC 13G/A 1 calaa520923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Calithera Biosciences, Inc. (Name of Issuer) COM (Title of Class of Securities) 13089P507 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 8, 2023 |
CALA / Calithera Biosciences Inc / INCYTE CORP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) January 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 25, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| January 25, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation |
|
| January 9, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) |
|
| January 9, 2023 |
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution EX-99.1 2 d406710dex991.htm EX-99.1 Exhibit 99.1 Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution SOUTH SAN FRANCISCO, Calif., January 9, 2023 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best intere |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Calithera Biosciences, Inc. (Name of Issuer) (Title of Class of Securities) 13089P507 (CUSIP Number) November 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| November 14, 2022 |
Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update ? Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 ? SOUTH SAN FRANCISCO, Calif., November 14, 2022 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Comm |
|
| September 29, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Com |
|
| August 16, 2022 |
OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2. |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| August 16, 2022 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment to the Asset Purchase Agreement This Amendment to the Asset Purchase Agreement (the ?Amendment?) is made and entered into as of May 23, 2022 (the ?Amendment Ef |
|
| August 15, 2022 |
EXHIBIT 99.1 Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights ? Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 ? SOUTH SAN FRANCISCO, Calif., August 15, 2022 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results f |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| July 6, 2022 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock of Calithera Biosciences, Inc. |
|
| July 6, 2022 |
CALA / Calithera Biosciences Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo M0 103-8668 Attn: Yoshihi |
|
| July 6, 2022 |
Exhibit 1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 14, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CALITHERA BIOSCIENCES, INC. CALITHERA BIOSCIENCES, INC. (the ?Company?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the Company is Calithera Biosciences, Inc. SECOND: The original name of the |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commissio |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 23, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF CALITHERA BIOSCIENCES, INC. Calithera Biosciences, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), DOES HEREBY CERTIFY: FIR |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| May 10, 2022 |
Exhibit 99.1 Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights ? Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 ? SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial |
|
| April 21, 2022 |
Exhibit 1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. |
|
| April 21, 2022 |
CALA / Calithera Biosciences Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku , Tokyo, 103-8668, Japan Attn: Yoshi |
|
| April 21, 2022 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock of Calithera Biosciences, Inc. |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 12, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commissi |
|
| April 11, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Calithera Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the und |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 13089P1 |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2022 As filed with the U.S. Securities and Exchange Commission on March 31, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2366329 (State or other jurisdiction of Incorporation or organization) |
|
| April 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 Calithera Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2014 Equity Incentive Plan (Common stock, $0.0001 par value per share) |
|
| March 31, 2022 |
Exhibit 4.1 CALITHERA BIOSCIENCES, INC. FORM OF SHORT-TERM COMMON STOCK PURCHASE WARRANT [] Warrant Shares: [] Initial Exercise Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| March 31, 2022 |
Exhibit 1.1 Calithera Biosciences, Inc. 18,518,519 Shares of Common Stock Short-Term Common Warrants to Purchase 18,518,519 Shares of Common Stock Long-Term Common Warrants to Purchase 18,518,519 Shares of Common Stock Underwriting Agreement New York, New York March 29, 2022 SVB Securities LLC H.C. Wainwright & Co., LLC as Representatives of the several Underwriters c/o SVB Securities LLC 255 Cali |
|
| March 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commiss |
|
| March 31, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-243731 Prospectus Supplement (To Prospectus Dated August 19, 2020) 18,518,519 Shares of Common Stock Short-Term Warrants to Purchase up to 18,518,519 Shares of Common Stock Long-Term Warrants to Purchase up to 18,518,519 Shares of Common Stock We are offering 18,518,519 shares of our common stock and accompanying (1) warrants |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36644 CALITHERA BIOSC |
|
| March 31, 2022 |
Exhibit 99.1 Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights ? Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 ? SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today anno |
|
| March 31, 2022 |
Exhibit 4.2 CALITHERA BIOSCIENCES, INC. FORM OF LONG-TERM COMMON STOCK PURCHASE WARRANT [] Warrant Shares: [] Initial Exercise Date: [ ], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| March 31, 2022 |
Exhibit 4.3 CALITHERA BIOSCIENCES, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Warrant Agent Warrant Agency Agreement Dated as of , 2022 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2022 (?Agreement?), between Calithera Biosciences, Inc., a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust com |
|
| March 29, 2022 |
SUBJECT TO COMPLETION, MARCH 29, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-243731 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities offered hereby has been declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus supplement and t |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 13089P |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Calithera Biosciences, Inc. (Name of Issuer) (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 9, 2022 |
CALA / Calithera Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Calithera Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 13089P101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| January 5, 2022 |
Targeting cancer, differently. Susan M. Molineaux, Ph.D. | Founder, President & Chief Executive Officer Exhibit 99.1 Forward-Looking Statements This presentation and the accompanying oral commentary contain ?forward?looking? statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as ?believe,? ?will,? ?may |
|
| January 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| December 30, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Comm |
|
| December 10, 2021 |
CALA / Calithera Biosciences Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form18510.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) CALITHERA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 13089P101 (CUSIP Number) November 30, 2021 (Date of Even |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Calithera Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Numbe |
|
| November 22, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Calithera Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of t |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| November 9, 2021 |
Calithera Biosciences Inc. Amended and Restated Severance Benefit Plan. EXHIBIT 10.1 Calithera Biosciences, Inc. Amended and Restated Severance Benefit Plan Approved by the Compensation Committee of the Board of Directors: August 28, 2017 Amended and Restated by the Compensation Committee of the Board of Directors: August 21, 2021 a. Introduction. The Calithera Biosciences, Inc. Severance Benefit Plan (the ?Plan?) is hereby established effective as set forth above. Th |
|
| November 9, 2021 |
Exhibit 10.3 CONFIDENTIAL EXECUTION VERSION [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT between Millennium Pharmaceuticals, Inc. and Calithera Biosciences, Inc. Dated as of October 18, 2021 TABLE OF CO |
|
| November 9, 2021 |
Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights ? Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals ? ? Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 ? ? Conference call and webcast sc |
|
| November 5, 2021 |
Exhibit 99.1 Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial ?KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat ?Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-280 for the treatment of cystic fibrosis SOUTH SAN FRANCISC |
|
| November 5, 2021 |
Exhibit 99.2 Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer ? Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors SOUTH SAN FRANCISCO, Calif., November 5, 2021 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| October 19, 2021 |
Targeting cancer, differently. Susan M. Molineaux, Ph.D. | Founder, President & Chief Executive Officer Exhibit 99.2 Forward-Looking Statements This presentation and the accompanying oral commentary contain ?forward?looking? statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as ?believe,? ?will,? ?may |
|
| October 19, 2021 |
Exhibit 99.1 Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals ? TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company?s precision oncology pipeline ? ? Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022 ? ? Calithera to host webcast and conference call today at 5:30 p.m. ET |
|
| October 19, 2021 |
Exhibit 3.1 CALITHERA BIOSCIENCES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Susan Molineaux, does hereby certify that: 1. She is the President and Chief Executive Officer of Calithera Biosciences, Inc., a Delaware corporation (the ?Corporation?). 2 |
|
| October 19, 2021 |
Exhibit 10.1 PREFERRED STOCK PURCHASE AGREEMENT TABLE OF CONTENTS 1. DEFINED TERMS USED IN THIS AGREEMENT 3 2. PURCHASE AND SALE OF PREFERRED STOCK 5 2.1 Sale and Issuance of Preferred Stock 5 2.2 Closing; Delivery; Adjustments 6 3. REPRESENTATION, WARRANTIES AND COVENANTS OF THE COMPANY 6 3.1 Organization, Good Standing, Corporate Power and Qualification 6 3.2 Company Capitalization 6 3.3 Subsidi |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| October 19, 2021 |
Exhibit 99.3 Risk Factors Our business involves significant risks, some of which are described below. You should carefully consider the following risk factors, in addition to the other information contained in the reports we file with the Securities and Exchange Commission, or the SEC. The occurrence of any of the events or developments described in the following risk factors could harm our busine |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction Identification No.) (C |
|
| August 5, 2021 |
Exhibit 99.1 Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights ? Cash and Cash Equivalents Totaled $92.2 million as of June 30, 2021 ? ? Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021? SOUTH SAN FRANCISCO, Calif., August 5, 2021 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechn |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commiss |
|
| July 8, 2021 |
CALA / Calithera Biosciences Inc / BIOTECHNOLOGY VALUE FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 Calithera Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 13089P101 (CUSIP Num |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commissi |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| May 6, 2021 |
Exhibit 99.1 Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights ?$102.9 Million in Cash and Investments at March 31, 2021? ? Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021? SOUTH SAN FRANCISCO, Calif., May 6, 2021 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering |
|
| May 6, 2021 |
Exhibit 10.1 FOURTH AMENDMENT TO LEASE AGREEMENT THIS FOURTH AMENDMENT TO LEASE AGREEMENT (this ?Fourth Amendment?) is made as effective as of January 1, 2021 (the ?Surrender Date?), and dated as of March 8, 2021, by and between ARE-TECHNOLOGY CENTER SSF, LLC, a Delaware limited liability company (?Landlord?), and CALITHERA BIOSCIENCES, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commission |
|
| April 23, 2021 |
DEF 14A 1 d122933ddef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for U |
|
| April 23, 2021 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 16, 2021 |
March 16, 2021 (File No. 333-254351) As filed with the U.S. Securities and Exchange Commission on March 16, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2366329 (State or other jurisdiction of Incorporation or organization) |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commiss |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36644 CALITHERA BIOSC |
|
| March 16, 2021 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021— SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Calithera Biosciences, Inc. (Title of Class of Securities) Common Stock, Par Value $0 |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) CALITHERA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing o |
|
| February 12, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Calithera Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 13089P101 (CUSIP Num |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Calithera Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 13089P101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| January 26, 2021 |
EX-99.1 2 d116517dex991.htm EX-99.1 Exhibit 99.1 CALITHERA BIOSCIENCES, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 18, 2014 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 19, 2014 IPO DATE: OCTOBER 1, 2014 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS AS OF , 2021 1. GENERAL. (a) Purpose. The Plan, through the grant of Awards, is intended to help the Company secure and |
|
| January 25, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) January 13, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| January 4, 2021 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint — Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline — Company to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT SOUTH SAN |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on November 5, 2020— SOUTH SAN FRANCISCO, Calif., November 5, 2020 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and develop |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| November 5, 2020 |
EXHIBIT 10.1 Calithera Biosciences, Inc. Restricted Stock Unit Grant Notice (2014 Equity Incentive Plan) Calithera Biosciences, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject |
|
| October 9, 2020 |
CALA / Calithera Biosciences, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2009 Washington, D. |
|
| September 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 19, 2020 |
424B5 1 d928329d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-243731 PROSPECTUS $75,000,000 Common Stock We have entered into a sales agreement with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an a |
|
| August 17, 2020 |
CORRESP August 17, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio Re: Calithera Biosciences, Inc. Registration Statement on Form S-3 File No. 333-243731 Acceleration Request Requested Date: August 19, 2020 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rul |
|
| August 10, 2020 |
Sales Agreement, by and between Calithera Biosciences, Inc. and Jefferies LLC, dated August 10, 2020 EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENT August 10, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Calithera Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’ |
|
| August 10, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 10, 2020 Registration No. |
|
| August 10, 2020 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights — Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020— SOUTH SAN FRANCISCO, Calif., August 10, 2020 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and develop |
|
| August 10, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 CALITHERA BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CALITHERA BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CALITHERA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associatio |
|
| August 10, 2020 |
EX-4.4 Exhibit 4.4 Calithera Biosciences, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif |
|
| August 10, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 CALITHERA BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CALITHERA BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CALITHERA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organi |
|
| August 10, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 CALITHERA BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CALITHERA BIOSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between CALITHERA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associatio |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Co |
|
| August 10, 2020 |
Amended and Restated Bylaws of Calithera Biosciences, Inc. EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF CALITHERA BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may |
|
| July 14, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Comm |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| May 26, 2020 |
SC 13G/A 1 sc13ga40742201005262020.htm AMENDMENT NO. 4 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Calithera Biosciences, Inc. (Name of Issuer) Common Stock, $0.0 |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| May 7, 2020 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 7, 2020— SOUTH SAN FRANCISCO, Calif., May 7, 2020 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel, |
|
| April 21, 2020 |
CALA / Calithera Biosciences, Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2020 |
our definitive proxy statement Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2020 |
Underwriting Agreement, dated April 15, 2020. EX-1.1 Exhibit 1.1 Calithera Biosciences, Inc. 5,000,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York April 15, 2020 Citigroup Global Markets Inc. c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Calithera Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell |
|
| April 16, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 16, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 Prospectus Supplement (To Prospectus Dated August 18, 2017) 5,000,000 Shares Common Stock We are offering 5,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “CALA.” On April 15, 2020, the closing price of our common stock on the Nasdaq Global Select |
|
| April 15, 2020 |
SUBJECT TO COMPLETION, APRIL 15, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities offered hereby has been declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus supplement |
|
| March 13, 2020 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Calithera Biosciences, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0 |
|
| March 13, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| March 11, 2020 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Fourth Quarter 2019 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 11, 2020— SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing |
|
| March 11, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED AUGUST 18, 2017) $50,000,000 Common Stock We have entered into a certain Open Market Sale Agreement, or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the ac |
|
| March 11, 2020 |
10-K 1 cala-10k20191231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File |
|
| March 11, 2020 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, $0.0001 par value per share (“Common Stock”) of Calithera Biosciences, Inc. (the “Company,” “we,” “our,” or “us”) , which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange A |
|
| March 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction Identification No.) (C |
|
| March 11, 2020 |
Power of Attorney (see signature page hereto). S-8 As filed with the U.S. Securities and Exchange Commission on March 11, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2366329 (State or other jurisdiction of Incorporation or organizat |
|
| March 11, 2020 |
Sales Agreement, dated March 11, 2020. EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT March 11, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Calithera Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Calithera Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 13089P101 (CUSIP Number) Decem |
|
| February 14, 2020 |
CALA / Calithera Biosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) CALITHERA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing o |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of Calithera Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) |
|
| February 7, 2020 |
CALA / Calithera Biosciences, Inc. / DELPHI VENTURES VIII LP - SCHEDULE 13D/A Activist Investment CUSIP NO. 13089P101 13D Page 1 of 11 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) (Amendment No. 3) Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Matth |
|
| January 16, 2020 |
8-K 1 d863687d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (C |
|
| January 13, 2020 |
Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance EX-99.1 2 d851491dex991.htm EX-99.1 Exhibit 99.1 Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance SOUTH SAN FRANCISCO, Calif., January 13, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-thr |
|
| January 10, 2020 |
CALA / Calithera Biosciences, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G Passive Investment OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2009 Washington, D. |
|
| December 6, 2019 |
Sales Agreement, dated December 6, 2019. EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT December 6, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Calithera Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company |
|
| December 6, 2019 |
424B5 1 d105105d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED AUGUST 18, 2017) $50,000,000 Common Stock We have entered into a certain Open Market Sale Agreement, or sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock, par value $0.0001 per share, offered by this prospe |
|
| December 6, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (C |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2019 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on November 12, 2019— SOUTH SAN FRANCISCO, Calif., November 12, 2019 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and devel |
|
| November 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 13089P101 (CUSIP Number) October 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 8, 2019 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019— SOUTH SAN FRANCISCO, Calif., August 8, 2019 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| June 25, 2019 |
SC 13G/A 1 sc13ga20742201006252019.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Calithera Biosciences, Inc. (Name of Issuer) Common stock, par |
|
| June 19, 2019 |
Underwriting Agreement, dated June 18, 2019. EX-1.1 Exhibit 1.1 Execution Calithera Biosciences, Inc. 12,500,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement June 18, 2019 SVB Leerink LLC Wells Fargo Securities, LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters, c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, CA 94111 c/o Wells Fargo Securities, LLC 375 Park Avenue, 4th |
|
| June 19, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 19, 2019 |
12,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 Prospectus Supplement (To Prospectus Dated August 18, 2017) 12,500,000 Shares Common Stock We are offering 12,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “CALA.” On June 18, 2019, the closing price of our common stock on the Nasdaq Global Selec |
|
| June 17, 2019 |
SUBJECT TO COMPLETION, DATED JUNE 17, 2019 424B5 1 d765113d424b5.htm 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities offered hereby has been declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus ar |
|
| June 3, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2019 |
CALA / Calithera Biosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) CALITHERA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 13089P101 (CUSIP Number) April 30, 2019 (Date of Event Which Requires Filing of t |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2019 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights —Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019— SOUTH SAN FRANCISCO, Calif., May 9, 2019 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development |
|
| May 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| April 5, 2019 |
CALA / Calithera Biosciences, Inc. DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2019 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2019 |
March 7, 2019 (File No. 333-230131) S-8 As filed with the U.S. Securities and Exchange Commission on March 7, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2366329 (State or other jurisdiction of Incorporation or organizati |
|
| March 7, 2019 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights -Calithera to Provide Corporate Update via Conference Call and Webcast at 1:30 p.m. PT on March 7, 2019 SOUTH SAN FRANCISCO, Calif., March 7, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing no |
|
| March 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d716155d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of |
|
| March 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36644 CALITHERA BIOSC |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Calithera Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Num |
|
| February 13, 2019 |
CALA / Calithera Biosciences, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) CALITHERA BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of |
|
| February 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 14, 2019 |
8-K 1 d691343d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction |
|
| January 7, 2019 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline SOUTH SAN FRANCISCO, Calif., January 7, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor meta |
|
| January 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d660091d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction |
|
| November 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (C |
|
| November 7, 2018 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights |
|
| November 7, 2018 |
CALA / Calithera Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| September 4, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 4, 2018 with respect to the common stock, par value $0.0001 per share of Calithera Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions o |
|
| September 4, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Calithera Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Numb |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d602208d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction o |
|
| August 7, 2018 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights -Two Novel Programs Entering Clinical Development -Calithera to Host Conference Call Today at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., August 7, 2018 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company f |
|
| August 7, 2018 |
CALA / Calithera Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| June 5, 2018 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2018 |
CALA / Calithera Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| May 10, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) ( |
|
| May 10, 2018 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights -Initiated Randomized Phase 2 CANTATA Trial -Presented Preclinical Data at the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering an |
|
| April 10, 2018 |
CALA / Calithera Biosciences, Inc. DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2018 |
CALA / Calithera Biosciences, Inc. DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2018 |
EX-99.5 Exhibit 99.5 CALITHERA BIOSCIENCES, INC. INDUCEMENT PLAN STOCK OPTION GRANT NOTICE Calithera Biosciences, Inc. (the “Company”), pursuant to its Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Opti |
|
| March 8, 2018 |
March 8, 2018 (File No. 333-223533) S-8 1 d544244ds8.htm S-8 As filed with the U.S. Securities and Exchange Commission on March 8, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2366329 (State or other jurisdiction of Incorp |
|
| March 8, 2018 |
EX-99.4 Exhibit 99.4 CALITHERA BIOSCIENCES, INC. INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: JANUARY 11, 2018 1. GENERAL. (a) Eligible Stock Award Recipients. The only persons eligible to receive grants of Stock Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) and the related guidance under NASDAQ IM 5635-1. |
|
| March 8, 2018 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights -Calithera to Webcast Corporate Update on March 8, 2018 SOUTH SAN FRANCISCO, Calif., March 8, 2018 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor |
|
| March 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d549265d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdicti |
|
| March 8, 2018 |
CALA / Calithera Biosciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36644 CALITHERA BIOSC |
|
| February 14, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2017 (Date of Event Which Req |
|
| February 13, 2018 |
SC 13G/A 1 p18-0220sc13ga.htm CALITHERA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This St |
|
| February 8, 2018 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 13089P101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Calithera Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 13089P101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 16, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2018 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (C |
|
| November 2, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (C |
|
| November 2, 2017 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights -Calithera to Webcast Clinical Update on CB-839 on November 11, 2017 SOUTH SAN FRANCISCO, Calif., November 2, 2017 (GLOBE NEWSWIRE) ? Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directe |
|
| November 2, 2017 |
CALA / Calithera Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| November 2, 2017 |
Calithera Biosciences Inc. Severance Benefit Plan. Exhibit 10.1 Calithera Biosciences, Inc. Severance Benefit Plan Approved by the Compensation Committee of the Board of Directors: August 28, 2017 Section 1. Introduction. The Calithera Biosciences, Inc. Severance Benefit Plan (the “Plan”) is hereby established effective as of the date set forth above (the “Effective Date). The purpose of the Plan is to provide for the payment of severance benefits |
|
| October 3, 2017 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Susan Molineaux, Stephanie Wong, John McKenna and Seth Gottlieb, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Calithera Biosciences, Inc. |
|
| September 28, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) September 26, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| September 21, 2017 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Susan Molineaux, Stephanie Wong, Sumita Ray, John McKenna and Seth Gottlieb, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of Calithera Biosciences, Inc. |
|
| September 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Com |
|
| August 28, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Co |
|
| August 18, 2017 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219791 PROSPECTUS $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock ha |
|
| August 16, 2017 |
CALA / Calithera Biosciences, Inc. ESP Acceleration Request August 16, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Re: Calithera Biosciences, Inc. Registration Statement on Form S-3 File No. 333-219791 Acceleration Request Requested Date: August 18, 2017 Requested Time: 4:00 PM Eastern Time Ladies and gentlemen: In accordance w |
|
| August 8, 2017 |
CALITHERA BIOSCIENCES, INC. COMMON STOCK SALES AGREEMENT EX-1.2 Exhibit 1.2 CALITHERA BIOSCIENCES, INC. $50,000,000.00 COMMON STOCK SALES AGREEMENT August 8, 2017 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Calithera Biosciences, Inc. (the Company), confirms its agreement (this Agreement) with Cowen and Company, LLC (Cowen), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to t |
|
| August 8, 2017 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2017 Registration No. |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) (Commiss |
|
| August 8, 2017 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights -Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., August 8, 2017 (GLOBE NEWSWIRE) Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small m |
|
| August 8, 2017 |
CALA / Calithera Biosciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| June 14, 2017 |
Calithera Biosciences FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) ( |
|
| June 7, 2017 |
CALA / Calithera Biosciences, Inc. / DELPHI VENTURES VIII LP - SC 13D/A Activist Investment CUSIP NO. 13089P101 13D Page 1 of 15 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) (Amendment No. 2) Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Matth |
|
| May 15, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction of incorporation) ( |
|
| May 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d390381d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 Calithera Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36644 27-2366329 (State or other jurisdiction |
|
| May 9, 2017 |
EX-99.1 Exhibit 99.1 Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights -Strong quarter-end cash position of $207.1 million supports advancement of multiple clinical development programs -Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 9, 2017 (GLOBE NEWSWIRE) Calithera Biosciences, I |
|
| May 9, 2017 |
EXHIBIT 10.2 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this ?Third Amendment?) is made as of February 28, 2017, by and between ARE-TECHNOLOGY CENTER SSF, LLC, a Delaware limited liability company (?Landlord?), and CALITHERA BIOSCIENCES, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as |
|
| May 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36644 CALITHERA BIOSCIENCES, INC. |
|
| May 9, 2017 |
EXHIBIT 10.1 EXECUTION VERSION [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENT by and between Incyte Corporation and Calithera Biosciences, Inc. dated as of January 2 |
|
| April 21, 2017 |
Calithera Biosciences DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
